Ref: Bio/Acts/ CS/ SE/ Ltrs- NSE/PR

Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

Date: March 9, 2015

The National Stock Exchange of India Limited
Exchange Plaza
Bandra – Kurla Complex
Bandra (East)
Mumbai- 400 051

"By Email & Courier"

Kind Attn: **Mr. Hari K.**

Subject: Intimation of Press Release

Please find enclosed a copy of press release made by the Company, on the topic:

"Biocon Strengthens its Presence in Mexico; Receives Approval for Insulin Glargine through its partner PiSA Farmaceutica"

Kindly take this intimation on record.

Thanking you.

Yours faithfully,
For Biocon Limited,

Kiran Kumar G
Company Secretary
E: Kiran.Kumar@biocon.com
M: +91 9945315151
T: +91 80 2808 2037

By Email to NSE: cmlist@nse.co.in

Press Release

Biocon Strengthens its Presence in Mexico; Receives Approval for Insulin Glargine through its partner PiSA Farmaceutica

Bangalore, India, April 9, 2015

Biocon Ltd. (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceuticals company, announced today that its Insulin Glargine has been approved by COFEPRIS, the Mexican health authority, through its partner PiSA Farmaceutica (PiSA).

Mexico has been a very important market for Biocon since 2006, where it has been playing a significant role in enabling access to affordable rh-Insulin. Insulin Glargine will augment the affordable insulins therapy for diabetes management. 'GALACTUS' by PiSA is the first Insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012.

Biocon is recognized as Asia's largest insulins producer and has been committed to affordable diabetes management through rh-Insulin (Insugen ®) and Insulin Glargine (Basalog ®) in India and several emerging markets. The company currently has marketing approvals in over 60 countries for rh-Insulin and in over 20 countries for Insulin Glargine.

Biocon Chairperson & Managing Director Kiran Mazumdar-Shaw said: *"We are committed to make global impact with our affordable insulins therapy. Our Insulin Glargine, will now enable access to a basal insulin which will further expand the diabetes management therapy for patients in Mexico."*

Ravi Limaye, President - Marketing, Biocon said: *"With Insulin Glargine approval in Mexico we have expanded our insulins global footprint. Along with our partner PiSA we will be able to enhance the reach of our affordable insulins therapy in the country."*

PiSA Group Executive Vice President Lic. Santiago Alvarez Vega said: "*We are extremely excited to partner with Biocon to introduce GALACTUS, the long acting insulin glargine in Mexico, which has a disease prevalence of 12%, the second highest in the world*. We hope to enable the government to bring down its per capita expenditure on diabetes with the use of this cost effective, high quality biocomparable Insulin Glargine*"

Diabetes is a major health risk in Mexico, over 70% of the Mexican population is overweight thus prone to developing diabetes. With over 9 million cases of diabetes, it poses a huge

disease burden for the government with per capita expenditure on diabetes being as high as USD 892.5. As per available data it is a leading cause of mortality in the country. *(Source: IDF)*

Biocon's presence in Mexico, over the last eight years, has expanded the insulins market substantially by initiating many more patients onto insulin therapy. The increasing affordability of Insulin Glargine will now enable Biocon and PiSA to expand this reach further. The combined market for Insulin Glargine in Mexico is estimated to be in excess of USD 40 million.

Note: * *Mexico ranks 6th globally with 9 mn diabetes cases and in the same pool of Top 10 countries, it ranks 2nd in disease prevalence.*

About Biocon Ltd

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 85 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb ™(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody. It has a rich pipeline of biosimilars and novel biologics at various stages of development including high potential oral insulin. Visit: www.biocon.com

About PiSA Farmaceutica

PiSA Farmaceutica, est. in 1945, is a privately held leading Mexican pharmaceutical company that has its strong presence in the Mexican market and select Latin American countries. PiSA through its 16,000 employees is committed to excellence and its customers. Over years PiSA has created a robust infrastructure for quality pharmaceutical development and manufacturing which helps generate, assimilate and transform new technologies that impact the pharmaceutical industry. PiSA's manufacturing complies with various regulatory requirements and helps cater to the demand for quality products required by its customers. With products like AGRIFEN, CEFAXONA, ELECTROLIT, INSULEX and DEXTRIFYL PiSA has been successfully creating top brands in the Mexican markets. PiSA has also established itself as a leading company for treating renal diseases through its reliability in Peritoneal Dialysis and Haemodialysis. Visit: www.pisa.com.mx

Contact Information	
Media Relations	
Seema Ahuja Head, Corporate Communications 080 2808 2222; +91 99723 17792 seema.ahuja@biocon.com	**Rumman Ahmed** Manager, Corporate Communications 080 2808 2223; +91 98451 04173 rumman.ahmed@biocon.com
Investor Relations	
Saurabh Paliwal Head, Investor Relations 080 2808 2040; +91 95383 80801 saurabh.paliwal@biocon.com	